help(2), page-7

I think it is fair to say that most people were surprised by the undue and totally illogical delay when approval referral to EMA was first announced. However, I am intrigued by the number of TIS share holders who still think that it was the fault of TIS or BIS at some point or the fault of some lazy public servants. Wise up people, streetwise I mean. No matter what TIS and or BIS had done, the result would have been the same. All the existing pharma’s in this field stand to lose big if/when TIS is approved. All stops were pulled to delay TIS. By the same token, the next stage of approval is likely to suffer some undue delays. Just be patient from now on? Forget it. Our oppositions love it if you believe that the next stage will be smooth sailing and just wait and wait patiently and do nothing!

In fact, I would argue that TIS future should not be left in only “one basket”. In pharmacy, it is not hard to devise similar products that have similar results. If you wait long enough, a generic product will be available and TIS may not have a future at all. For any business to survive these days, one must think outside the square, be innovative. One must have Plan A, B, C even D and sometimes all at once!

I am in favour of trying for approval in Australia.